Cargando…

ACT-6 Clinical manifestations of the patients with relapsed glioblastoma after bevacizumab treatment

Introduction:The outcome of glioblastoma (GBM) is improving recently, but still only temozolomide and bevacizumab (BEV) are recognized as the effective agents that are reimbursed in Japan. On large clinical trials, BEV prolonged progression free survival (PFS) but the remaining survival period from...

Descripción completa

Detalles Bibliográficos
Autores principales: Kikuchi, Miyu, Takahashi, Masamichi, Yanagisawa, Syunsuke, Ono, Makoto, Miyakita, Yasuji, Tamura, Yukie, Kawauchi, Daisuke, Narita, Yoshitaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664617/
http://dx.doi.org/10.1093/noajnl/vdab159.036
_version_ 1784613878739501056
author Kikuchi, Miyu
Takahashi, Masamichi
Yanagisawa, Syunsuke
Ono, Makoto
Miyakita, Yasuji
Tamura, Yukie
Kawauchi, Daisuke
Narita, Yoshitaka
author_facet Kikuchi, Miyu
Takahashi, Masamichi
Yanagisawa, Syunsuke
Ono, Makoto
Miyakita, Yasuji
Tamura, Yukie
Kawauchi, Daisuke
Narita, Yoshitaka
author_sort Kikuchi, Miyu
collection PubMed
description Introduction:The outcome of glioblastoma (GBM) is improving recently, but still only temozolomide and bevacizumab (BEV) are recognized as the effective agents that are reimbursed in Japan. On large clinical trials, BEV prolonged progression free survival (PFS) but the remaining survival period from the relapse after BEV is only 3–5 month. On this study, we retrospectively analyzed the data of GBM patients who were treated with BEV to explore the best usage of BEV.Methods:230 patients were diagnosed as GBM and received BEV from July 2013 to March 2021 in our institution. Among them, 104 patient, whose clinical courses were followed, were included in this study. (M:F=59:45, median age was 65.5) Results:The patients were divided into three groups by when they used BEV; upfront group at first line therapy, 1st relapse group at second line, and 2nd+ relapse group at more than third line. There were 42, 35, 27 patients in each group. The median overall survival (OS) was 17.6, 24.7, 46.1 month (p<0.0001), median PFS after BEV treatment (PFSpBEV) was 8.8, 5.1, 5.0 month (p=0.2532), and the median survival after BEV treatment (OSpBEV) was 15.0, 9.9, 9.2 month (p=0.4437), respectively. There were 64 patients (22, 25, 17 in each group) who reached progressive disease (PD) after BEV. The median survival after PD (OSpBEVpPD) was 4.5, 5.8, 4.3 month (p=0.1590), respectively.Discussion:At the first onset, we use BEV only when the patients have low PS. Our results showed that OS was significantly longer when BEV was used in the later stage, but there was no significant difference in OS or PFS after BEV treatment. Especially OSpBEVpPD was 4–6 month regardless of the timing of BEV. To improve the treatment outcome of GBM, breakthrough therapy is needed in addition to optimizing the usage of BEV.
format Online
Article
Text
id pubmed-8664617
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-86646172021-12-13 ACT-6 Clinical manifestations of the patients with relapsed glioblastoma after bevacizumab treatment Kikuchi, Miyu Takahashi, Masamichi Yanagisawa, Syunsuke Ono, Makoto Miyakita, Yasuji Tamura, Yukie Kawauchi, Daisuke Narita, Yoshitaka Neurooncol Adv Supplement Abstracts Introduction:The outcome of glioblastoma (GBM) is improving recently, but still only temozolomide and bevacizumab (BEV) are recognized as the effective agents that are reimbursed in Japan. On large clinical trials, BEV prolonged progression free survival (PFS) but the remaining survival period from the relapse after BEV is only 3–5 month. On this study, we retrospectively analyzed the data of GBM patients who were treated with BEV to explore the best usage of BEV.Methods:230 patients were diagnosed as GBM and received BEV from July 2013 to March 2021 in our institution. Among them, 104 patient, whose clinical courses were followed, were included in this study. (M:F=59:45, median age was 65.5) Results:The patients were divided into three groups by when they used BEV; upfront group at first line therapy, 1st relapse group at second line, and 2nd+ relapse group at more than third line. There were 42, 35, 27 patients in each group. The median overall survival (OS) was 17.6, 24.7, 46.1 month (p<0.0001), median PFS after BEV treatment (PFSpBEV) was 8.8, 5.1, 5.0 month (p=0.2532), and the median survival after BEV treatment (OSpBEV) was 15.0, 9.9, 9.2 month (p=0.4437), respectively. There were 64 patients (22, 25, 17 in each group) who reached progressive disease (PD) after BEV. The median survival after PD (OSpBEVpPD) was 4.5, 5.8, 4.3 month (p=0.1590), respectively.Discussion:At the first onset, we use BEV only when the patients have low PS. Our results showed that OS was significantly longer when BEV was used in the later stage, but there was no significant difference in OS or PFS after BEV treatment. Especially OSpBEVpPD was 4–6 month regardless of the timing of BEV. To improve the treatment outcome of GBM, breakthrough therapy is needed in addition to optimizing the usage of BEV. Oxford University Press 2021-12-06 /pmc/articles/PMC8664617/ http://dx.doi.org/10.1093/noajnl/vdab159.036 Text en © The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Supplement Abstracts
Kikuchi, Miyu
Takahashi, Masamichi
Yanagisawa, Syunsuke
Ono, Makoto
Miyakita, Yasuji
Tamura, Yukie
Kawauchi, Daisuke
Narita, Yoshitaka
ACT-6 Clinical manifestations of the patients with relapsed glioblastoma after bevacizumab treatment
title ACT-6 Clinical manifestations of the patients with relapsed glioblastoma after bevacizumab treatment
title_full ACT-6 Clinical manifestations of the patients with relapsed glioblastoma after bevacizumab treatment
title_fullStr ACT-6 Clinical manifestations of the patients with relapsed glioblastoma after bevacizumab treatment
title_full_unstemmed ACT-6 Clinical manifestations of the patients with relapsed glioblastoma after bevacizumab treatment
title_short ACT-6 Clinical manifestations of the patients with relapsed glioblastoma after bevacizumab treatment
title_sort act-6 clinical manifestations of the patients with relapsed glioblastoma after bevacizumab treatment
topic Supplement Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664617/
http://dx.doi.org/10.1093/noajnl/vdab159.036
work_keys_str_mv AT kikuchimiyu act6clinicalmanifestationsofthepatientswithrelapsedglioblastomaafterbevacizumabtreatment
AT takahashimasamichi act6clinicalmanifestationsofthepatientswithrelapsedglioblastomaafterbevacizumabtreatment
AT yanagisawasyunsuke act6clinicalmanifestationsofthepatientswithrelapsedglioblastomaafterbevacizumabtreatment
AT onomakoto act6clinicalmanifestationsofthepatientswithrelapsedglioblastomaafterbevacizumabtreatment
AT miyakitayasuji act6clinicalmanifestationsofthepatientswithrelapsedglioblastomaafterbevacizumabtreatment
AT tamurayukie act6clinicalmanifestationsofthepatientswithrelapsedglioblastomaafterbevacizumabtreatment
AT kawauchidaisuke act6clinicalmanifestationsofthepatientswithrelapsedglioblastomaafterbevacizumabtreatment
AT naritayoshitaka act6clinicalmanifestationsofthepatientswithrelapsedglioblastomaafterbevacizumabtreatment